Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Knispel

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
International Urology and Nephrology|November 25, 2005
A new option for the management of urethral trauma: primary reconstruction of posterior urethral disruption with a buccal mucosa transplantB Stürzebecher, H Schulte-Baukloh, V Brenneke, et al.
Neurourology and Urodynamics|February 14, 2006
Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysisH Schulte-Baukloh, J Schobert, T Stolze, et al.
Urology|February 11, 1998
Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexiaC Goessl, H H Knispel, U Fiedler, et al.
BJU International|January 25, 2006
Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysisHeinrich Schulte-Baukloh, Gerd Mürtz, Thomas Henne, et al.
Aktuelle Urologie|July 8, 2005
[Subjective patient satisfaction after injection of botulinum-a toxin in detrusor overactivity]H Schulte-Baukloh, C Weiss, J Schobert, et al.
Urology|February 20, 2013
Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind studyHeinrich Schulte-Baukloh, Judith Priefert, Helmut H Knispel, et al.
European Urology|January 1, 1993
Mixed gonadal dysgenesis associated with unilateral cavernosal fibrosis and presenting as a cystic lower abdominal massH E Wegner, R Klän, R D Wegner, et al.
BJU International|September 6, 2007
Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatmentHeinrich Schulte-Baukloh, Tomas H Zurawski, Helmut H Knispel, et al.
European Urology|August 30, 2005
Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfactionHeinrich Schulte-Baukloh, Catarina Weiss, Thomas Stolze, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 3, 2008
Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failureHeinrich Schulte-Baukloh, Hans Bigalke, Kurt Miller, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
International Urology and Nephrology|November 25, 2005
A new option for the management of urethral trauma: primary reconstruction of posterior urethral disruption with a buccal mucosa transplantB Stürzebecher, H Schulte-Baukloh, V Brenneke, et al.
Neurourology and Urodynamics|February 14, 2006
Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysisH Schulte-Baukloh, J Schobert, T Stolze, et al.
Urology|February 11, 1998
Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexiaC Goessl, H H Knispel, U Fiedler, et al.
BJU International|January 25, 2006
Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysisHeinrich Schulte-Baukloh, Gerd Mürtz, Thomas Henne, et al.
Aktuelle Urologie|July 8, 2005
[Subjective patient satisfaction after injection of botulinum-a toxin in detrusor overactivity]H Schulte-Baukloh, C Weiss, J Schobert, et al.
Urology|February 20, 2013
Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind studyHeinrich Schulte-Baukloh, Judith Priefert, Helmut H Knispel, et al.
European Urology|January 1, 1993
Mixed gonadal dysgenesis associated with unilateral cavernosal fibrosis and presenting as a cystic lower abdominal massH E Wegner, R Klän, R D Wegner, et al.
BJU International|September 6, 2007
Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatmentHeinrich Schulte-Baukloh, Tomas H Zurawski, Helmut H Knispel, et al.
European Urology|August 30, 2005
Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfactionHeinrich Schulte-Baukloh, Catarina Weiss, Thomas Stolze, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 3, 2008
Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failureHeinrich Schulte-Baukloh, Hans Bigalke, Kurt Miller, et al.
Pageof 6